FDA Grants Breakthrough Therapy Designation to Renibus Therapeutics' RBT-1 for Cardiothoracic Surgery Complications
Renibus Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in the prevention and treatment of cardio-renal diseases, recently made an announcement regarding the Breakthrough Therapy designation granted to their drug candidate, RBT-1, by the U.S. Food and Drug Administration (FDA). This designation signifies the potential of RBT-1 to significantly improve post-operative outcomes in patients undergoing cardiothoracic surgery.
RBT-1 is a pharmacological pre-conditioning agent being developed by Renibus. Its purpose is to reduce the risk of post-operative complications in patients undergoing cardiothoracic surgery. The Phase 2 study of RBT-1, completed in February 2023, was a randomized, double-blind, placebo-controlled trial conducted at multiple centers. It focused on evaluating the effects of RBT-1 in patients undergoing elective coronary artery bypass graft (CABG) and/or cardiac valve surgery.
RBT-1, also known as stannic protoporfin/iron sucrose, exhibits potent properties as an inducer of anti-inflammatory, antioxidant, and iron-scavenging pathways. These characteristics make it a promising candidate for improving post-operative outcomes in cardiothoracic surgery patients. Renibus sees the Breakthrough Therapy designation as a significant achievement that highlights their dedication to creating a new drug category.
The Breakthrough Therapy designation is intended to streamline the development and review process for drugs targeting serious or life-threatening diseases when there is evidence suggesting substantial improvements over existing therapies. Renibus will now proceed with Phase 3 development to further investigate the effectiveness and safety of RBT-1 in reducing post-operative complications following cardiothoracic surgery.
